169 related articles for article (PubMed ID: 21521860)
21. Role of levetiracetam in the treatment of epilepsy.
Brodie MJ; French JA
Epileptic Disord; 2003 May; 5 Suppl 1():S65-72. PubMed ID: 12915344
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of levetiracetam (3,000 mg/Day) as an adjunctive therapy in Chinese patients with refractory partial seizures.
Xiao Z; Li JM; Wang XF; Xiao F; Xi ZQ; Lv Y; Sun HB
Eur Neurol; 2009; 61(4):233-9. PubMed ID: 19176965
[TBL] [Abstract][Full Text] [Related]
23. Increased levetiracetam clearance and breakthrough seizure in a pregnant patient successfully handled by intensive therapeutic drug monitoring.
Cappellari AM; Cattaneo D; Clementi E; Kustermann A
Ther Drug Monit; 2015 Jun; 37(3):285-7. PubMed ID: 25384117
[TBL] [Abstract][Full Text] [Related]
24. Generic substitution of antiepileptic drugs.
Sander JW; Ryvlin P; Stefan H; Booth DR; Bauer J
Expert Rev Neurother; 2010 Dec; 10(12):1887-98. PubMed ID: 21091318
[TBL] [Abstract][Full Text] [Related]
25. Levetiracetam for seizures in children with brain tumors and other cancers.
Partap S; Fisher PG
Pediatr Blood Cancer; 2009 Feb; 52(2):288-9. PubMed ID: 18831033
[TBL] [Abstract][Full Text] [Related]
26. Generic substitution in the treatment of epilepsy: patient and physician perceptions.
Berg MJ; Gross RA; Haskins LS; Zingaro WM; Tomaszewski KJ
Epilepsy Behav; 2008 Nov; 13(4):693-9. PubMed ID: 18589000
[TBL] [Abstract][Full Text] [Related]
27. Rapid infusion of a loading dose of intravenous levetiracetam with minimal dilution: a safety study.
Wheless JW; Clarke D; Hovinga CA; Ellis M; Durmeier M; McGregor A; Perkins F
J Child Neurol; 2009 Aug; 24(8):946-51. PubMed ID: 19264738
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic drug monitoring of levetiracetam by high-performance liquid chromatography with photodiode array ultraviolet detection: preliminary observations on correlation between plasma concentration and clinical response in patients with refractory epilepsy.
Lancelin F; Franchon E; Kraoul L; Garciau I; Brovedani S; Tabaouti K; Landré E; Chassoux F; Paubel P; Piketty ML
Ther Drug Monit; 2007 Oct; 29(5):576-83. PubMed ID: 17898647
[TBL] [Abstract][Full Text] [Related]
29. Levetiracetam.
Beaulieu MJ
Neonatal Netw; 2013; 32(4):285-8. PubMed ID: 23835548
[TBL] [Abstract][Full Text] [Related]
30. Switching from branded to generic antiepileptic drugs as a confounding factor and unpredictable diagnostic pitfall in epilepsy management.
Di Bonaventura C; Fattouch J; Fabbrini G; Manfredi M; Prencipe M; Giallonardo TA
Epileptic Disord; 2007 Dec; 9(4):465-6. PubMed ID: 18055310
[No Abstract] [Full Text] [Related]
31. Pharmacokinetics of levetiracetam in neonates with seizures.
Merhar SL; Schibler KR; Sherwin CM; Meinzen-Derr J; Shi J; Balmakund T; Vinks AA
J Pediatr; 2011 Jul; 159(1):152-154.e3. PubMed ID: 21592494
[TBL] [Abstract][Full Text] [Related]
32. Intravenous levetiracetam in the management of acute seizures in children.
Reiter PD; Huff AD; Knupp KG; Valuck RJ
Pediatr Neurol; 2010 Aug; 43(2):117-21. PubMed ID: 20610122
[TBL] [Abstract][Full Text] [Related]
33. Safety of Overnight Switch from Brand-Name to Generic Levetiracetam.
Vari MS; Pinto F; Mencaroni E; Giudizioso G; Minetti C; La Neve A; Francavilla T; Piccioli M; Striano S; del Gaudio L; Tovo P; Striano P; Verrotti A
Clin Drug Investig; 2016 Jan; 36(1):87-91. PubMed ID: 26507620
[TBL] [Abstract][Full Text] [Related]
34. Influence of levetiracetam on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice.
Donato Di Paola E; Gareri P; Davoli A; Gratteri S; Scicchitano F; Naccari C; De Sarro G
Epilepsy Res; 2007 Jul; 75(2-3):112-21. PubMed ID: 17553669
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy.
Li S; Cao J; Xiao N; Cai F
J Child Neurol; 2010 May; 25(5):609-13. PubMed ID: 19779208
[TBL] [Abstract][Full Text] [Related]
36. Intravenous levetiracetam in children with seizures: a prospective safety study.
Ng YT; Hastriter EV; Cardenas JF; Khoury EM; Chapman KE
J Child Neurol; 2010 May; 25(5):551-5. PubMed ID: 20413804
[TBL] [Abstract][Full Text] [Related]
37. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures.
Wu XY; Hong Z; Wu X; Wu LW; Wang XF; Zhou D; Zhao ZX; Lv CZ
Epilepsia; 2009 Mar; 50(3):398-405. PubMed ID: 18657175
[TBL] [Abstract][Full Text] [Related]
38. Accidental overdosage of levetiracetam in two children caused no side effects.
Awaad Y
Epilepsy Behav; 2007 Sep; 11(2):247. PubMed ID: 17692573
[No Abstract] [Full Text] [Related]
39. Efficacy and safety of levetiracetam 1000-3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open-label single-arm study.
Beran RG; Berkovic SF; Black AB; Danta G; Hiersemenzel R; Schapel GJ; Vajda FJ
Epilepsy Res; 2005 Jan; 63(1):1-9. PubMed ID: 15716083
[TBL] [Abstract][Full Text] [Related]
40. Use of levetiracetam in special populations.
French J
Epilepsia; 2001; 42 Suppl 4():40-3. PubMed ID: 11564125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
